• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. - Common Stock (NQ:HELP)

5.770 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. - Common Stock

News headline image
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
Today 7:30 EDT
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks –  Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Supports Executive Order Advancing Psychedelic Therapies
April 20, 2026
Via Investor Brand Network
InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) CEO Steps Down, Eric So Named Interim Chief Executive Office
April 20, 2026
Via Investor Brand Network
News headline image
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
April 20, 2026
From Helus Pharma
Via GlobeNewswire
News headline image
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
April 20, 2026
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Ken Kramer SVP Medical Affairs
April 16, 2026
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
April 16, 2026
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer
March 12, 2026
Via Investor Brand Network
News headline image
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
March 12, 2026
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2 Results for HLP004 in Generalized Anxiety Disorder
March 05, 2026
Via Investor Brand Network
News headline image
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
March 05, 2026
EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
March 05, 2026
From Helus Pharma
Via GlobeNewswire
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
February 24, 2026
Via Investor Brand Network
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
February 24, 2026
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release... 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
February 24, 2026
From Helus Pharma
Via GlobeNewswire
PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
February 17, 2026
Via Investor Brand Network
News headline image
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
February 17, 2026
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Q3 2025 Results, Advances Phase 3 and Phase 2 Programs
February 13, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
February 13, 2026
From Helus Pharma
Via GlobeNewswire
BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Michael Cola as Chief Executive Officer
February 10, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
February 10, 2026
EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
From Helus Pharma
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap